In Brief: Biogen's Avonex
Biogen's Avonex: Berlex motion to block approval of the beta interferon product for multiple sclerosis is denied by D.C. federal court Judge James Robertson April 30. Berlex still could file for an injunction upon approval of Avonex. The marketer of Betaseron filed a lawsuit on April 26 claiming that Avonex violates Betaseron orphan exclusivity and that Biogen has not shown comparability between the beta interferon product it will manufacture and market and the product used in clinical trials manufactured by Dr. Rentschler Arzneimittel, GmbH in Germany ("The Pink Sheet" April 29, p. 15)...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth